Collaborating with Alexander Scriabine and the Miles Institute for Preclinical Pharmacology

This article represents a timely opportunity to express my affection, admiration and gratitude to Professor David Triggle. David was my Ph.D. advisor as well as a key consultant in the 1980s and early 1990s for research programs at Miles Institute for Preclinical Pharmacology in West Haven, CT, the...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical pharmacology 2015-11, Vol.98 (2), p.318-321
Main Author: Janis, Ronald A.
Format: Article
Language:English
Subjects:
Academies and Institutes - history
Anandamide
Animals
Arachidonic Acids - history
Arachidonic Acids - isolation & purification
Arachidonic Acids - metabolism
Brain - metabolism
Calcium channel drugs
Calcium Channels - history
Calcium Channels - physiology
Cooperative Behavior
Dihydropyridines - history
Dihydropyridines - metabolism
Drug Discovery - history
Endocannabinoid
Endocannabinoids - history
Endocannabinoids - isolation & purification
Endocannabinoids - metabolism
Endogenous ligand
History, 20th Century
History, 21st Century
Humans
Ligands
Polyunsaturated Alkamides - history
Polyunsaturated Alkamides - isolation & purification
Polyunsaturated Alkamides - metabolism
Potassium channel ligands
Potassium Channels - history
Potassium Channels - physiology
Research - history
Scriabine
Triggle
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This article represents a timely opportunity to express my affection, admiration and gratitude to Professor David Triggle. David was my Ph.D. advisor as well as a key consultant in the 1980s and early 1990s for research programs at Miles Institute for Preclinical Pharmacology in West Haven, CT, the U.S. research operation of Bayer AG, in the areas of Ca2+ and K+ channel ligands. The binding methodology developed in his laboratory was used to search for an endogenous ligand for L-type Ca2+ channels. We did not find the substance that we were searching for, a genetically-determined, competitive inhibitor for the 1,4-dihydropyridine binding site, but instead isolated the endogenous ligand for the brain's own marijuana, anandamide. Devane, Mechoulam and coworkers first discovered that this compound was the endogenous ligand for delta-9-tetrahydrocannabinol, the active substance in cannabis. The endogenous endocannabinoid system is now the target of many exciting new approaches to drug discovery.
ISSN:0006-2952
1873-2968
DOI:10.1016/j.bcp.2015.06.017